About Kadimastem
Kadimastem is a publicly listed company based in Ness Ziona (Israel) founded in 2009. Stem cell therapies for diabetes and ALS are developed. The company has 11 employees. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells.
Company details
Founded in 2009 and based in Ness Ziona, Israel, regenerative medicine efforts are directed toward developing and commercializing stem cell-based therapeutics for diabetes mellitus and amyotrophic lateral sclerosis. Proprietary technologies are used to differentiate stem cells into insulin-secreting beta cells and neural cells such as astrocytes and oligodendrocytes. Therapeutic programs are advanced for implantation to address disease progression, with collaborations focused on drug development using pluripotent stem cell-derived cells.
- Headquarters Ness Ziona, Israel
- Employees 11
- Stage Public
- SectorsHealthcare
- Website kadimastem.com
- Social LinkedIn Facebook Instagram
- Legal Name Kadimastem Ltd.
- Net Profit-$7.28 M (USD)-121.1as on Dec 31, 2024
- EBITDA-$1.39 M (USD)42as on Dec 31, 2024
- Latest Funding Round$5.01M (USD), Post-IPO
Oct 2021
- InvestorsEuropean Union
& 8 more
- Employee Count11
Funding Insights of Kadimastem
- Total Rounds 5
- Last Round Post-IPO — $5.01M
- First Round $705,846
(Jan 2016)
- Investors Count 9
All 5 funding rounds of Kadimastem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $5.01M | Post-IPO | – | – | |
| Oct 2018 | $5.15M | Post-IPO | – | – | |
| Mar 2018 | $319,372 | Grant | – | – | |
| Dec 2016 | $7M | Post-IPO | – | – | |
| Jan 2016 | $705,846 | Grant | – | – |
9 investors in total: 5 institutional and 4 angel.
Investors in Kadimastem
Kadimastem has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, Altshuler Shaham and Clover Wolf Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management services are provided to various clients. | 1990 | as-invest.co.il | Tel Aviv, Israel | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
CorestemChemon is engaged in stem cell therapy and non-clinical research. | corestemchemon.com | Seongnam, South Korea | ||
YF Yehuda Feinberg | unknown_62c0d57d805547f19 | |||
MI Michal Izrael | unknown_14d64ac730ce4dfab | |||
CR Claire Revel | unknown_c1ea75ed6d4a45e68 | |||
JR Julien Ruggieri | unknown_5d6b577c86ca4dc09 |
Investor details for Kadimastem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kadimastem
21 people are tracked at Kadimastem (4 in leadership, 11 in board & advisors, 6 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Kfir Molakandov | Director | Leadership |
Asaf Shiloni | Chief Executive Officer | Leadership |
Uri Ben-Or | Chief Financial Officer | Leadership |
Michel Revel | Chief Scientist | Leadership |
Ben Reubinoff | Advisor | Board & advisors |
Danielle Melloul | Advisor | Board & advisors |
Eddy Karnieli | Advisor | Board & advisors |
Tamir Ben Hur | Advisor | Board & advisors |
Ronen Twito | Chairmen | Board & advisors |
Olivier Samuel | Director | Board & advisors |
Jeanne F. Loring | Advisor | Board & advisors |
Doron Birger | Director | Board & advisors |
Ron Mayron | Director | Board & advisors |
Joseph Itskovitz - Eldor | Advisor | Board & advisors |
Shimon Efrat | Advisor | Board & advisors |
Hanna Oppenheimer | Research Assistant | Team |
Michal Werbner | Reaserch Assistant | Team |
Shir Klein - Lavi | Research And Development Scientist | Team |
Itzik Toledo | Associate Researcher | Team |
Daniel Lazar | Research And Development Scientist | Team |
1 more people are available in the full profile.
Complete people profiles for Kadimastem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kadimastem
Kadimastem is a publicly listed company on the TASE with ticker symbol KDST in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jun 2013
- Listed onTLV: KDST
- Listed entityKadimastem Ltd.
- Exchange sectorHealth technology
- Share price3,541.00 ILA (+1.46% on the day) · 2025-09-29
- Market capitalisation148,798,080.00 ILA
- EPS (diluted, trailing year)-14.18 ILA
- Volume (last session)532
- Analyst consensusNeutral
Financials of Kadimastem
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -26.6M ILS | -5.1M ILS | |
| 2023 | -12.0M ILS | -8.8M ILS | |
| 2022 | -22.7M ILS | -20.1M ILS | |
| 2021 | -26.3M ILS | -22.4M ILS | |
| 2020 | -21.7M ILS | -18.5M ILS |
Detailed financial statements for Kadimastem
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kadimastem
4 dated milestones of Kadimastem across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Kadimastem is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $706K.
- Funding Latest funding round, Post-IPO, of $5.0M.
Web traffic of Kadimastem
The website of Kadimastem (kadimastem.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▲ 821.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kadimastem
Complete news archive for Kadimastem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kadimastem
Kadimastem was founded in 2009 and raised its 1st funding round 7 years after it was founded.
Kadimastem is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Kadimastem has 11 employees.
Founded in 2009 and based in Ness Ziona, Israel, regenerative medicine efforts are directed toward developing and commercializing stem cell-based therapeutics for diabetes mellitus and amyotrophic lateral sclerosis. Proprietary technologies are used to differentiate stem cells into insulin-secreting beta cells and neural cells such as astrocytes and oligodendrocytes. Therapeutic programs are advanced for implantation to address disease progression, with collaborations focused on drug development using pluripotent stem cell-derived cells.
Yes, Kadimastem is publicly traded on TASE under the ticker symbol KDST.
Kadimastem has 9 investors. Key investors include European Union, Altshuler Shaham, Clover Wolf Capital, Alpha Capital Anstalt, and Yehuda Feinberg.